Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]

Affiliations

• ¹ University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: [email protected].
• ² Catalan Institute of Oncology, Barcelona, Spain.
• ³ Institut Paoli Calmettes, Marseille, France.
• ⁴ Auckland City Hospital, Auckland, New Zealand; University of Auckland, Auckland, New Zealand.
• ⁵ Studienpraxis Urologie, Nürtingen, Germany.
• ⁶ Centre Eugène Marquis, Rennes, France.
• ⁷ General University Hospital Gregorio Marañón, Madrid, Spain.
• ⁸ Hôpital Européen Georges Pompidou, University of Paris, Paris, France.
• ⁹ Gustave Roussy, Cancer Campus, Villejuif, France; Paris-Saclay University, Villejuif, France.
• ¹⁰ Saarland University Medical Center, Homburg, Germany; Faculty of Medicine, Saarland University, Homburg, Germany.
• ¹¹ GU Research Network-Urology Cancer Center, Omaha, NE, USA.
• ¹² Vall d'Hebron Institute of Oncology, Vall d'Hebron, Barcelona, Spain.
• ¹³ Cross Cancer Institute and University of Alberta, Edmonton, AB, Canada.
• ¹⁴ Paracelsus Medical University, Nuremberg, Germany.
• ¹⁵ Macquarie University, Sydney, Australia.
• ¹⁶ University of Wollongong, Wollongong, NSW, Australia.
• ¹⁷ Merck & Co., Inc., Rahway, NJ, USA.
• ¹⁸ The Institute of Cancer Research and the Royal Marsden, London, UK.